The Effect of Opiates on Bone Formation and Bone Healing.


Journal

Current osteoporosis reports
ISSN: 1544-2241
Titre abrégé: Curr Osteoporos Rep
Pays: United States
ID NLM: 101176492

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 7 4 2020
medline: 19 8 2021
entrez: 7 4 2020
Statut: ppublish

Résumé

Opioids have been shown to be associated with an increased risk of fracture. The purpose of this paper is to review recent research into the effects of opioids on bone formation and bone healing in animal models and in human studies. Most opioids, such as morphine and fentanyl, negatively affected bone remodeling and bone healing in animal models. Conversely, remifentanil has been recently shown to promote in vitro osteoblast differentiation and to inhibit differentiation and maturation of osteoclasts, therefore reducing bone resorption. According to the possible negative role of opioids in bone healing, opioid antagonists have been shown to enhance bone mineralization, suggesting a possible therapeutic role in the future for osteoporosis. Other neuropeptides, such as the vasoactive intestinal peptide (VIP) and the neuropeptide Y (NPY), have been proved to promote osteogenesis. The increased risk of fractures among opioid users may be related to their central nervous system side effects or to the reduced bone density, partly due to their endocrine effects, and partly to their direct activity on bone cells. Clinical data strongly suggested a potential negative effect of opioids in bone healing. The risk of nonunion fracture is significantly increased in opioid users, and bone mass density was reduced in patients under long-term opioid treatment. The direct effects of opioids on bone remodeling appears evident from these reports. Not all opioids have the same potential for negatively impacting bone healing. Opioid antagonists may increase bone density and could represent a possible future treatment for low bone mass density pathologies. However, further trials are warranted to clarify the clinical relevance of these emerging findings from animal studies.

Identifiants

pubmed: 32249381
doi: 10.1007/s11914-020-00585-4
pii: 10.1007/s11914-020-00585-4
doi:

Substances chimiques

Analgesics, Opioid 0
Narcotic Antagonists 0
Neuropeptide Y 0
Vasoactive Intestinal Peptide 37221-79-7

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

325-335

Auteurs

Flaminia Coluzzi (F)

Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Corso della Repubblica 79, 04100, Latina, Italy. flaminia.coluzzi@uniroma1.it.
Unit of Anaesthesia, Intensive Care Medicine and Pain Therapy, AUSL Latina c/o ICOT, Latina, Italy. flaminia.coluzzi@uniroma1.it.

Maria Sole Scerpa (MS)

Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Corso della Repubblica 79, 04100, Latina, Italy.
Unit of Anaesthesia, Intensive Care Medicine and Pain Therapy, AUSL Latina c/o ICOT, Latina, Italy.

Marco Centanni (M)

Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Corso della Repubblica 79, 04100, Latina, Italy.
Endocrinology Unit, Santa Maria Goretti Hospital, AUSL Latina, Latina, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH